On Tuesday, Canaccord Genuity updated its outlook on shares of Travere Therapeutics (NASDAQ:TVTX), raising the price target to $23.00 from the previous $18.00, while maintaining a Buy rating on the stock. The adjustment comes in response to the FDA granting full approval for Travere's drug Filspari, used in the treatment of IgA Nephropathy (IgAN).
The full approval by the FDA has led to an expansion of the drug's indication, now making it available to all patients with IgAN at risk for disease progression. Previously, the drug was recommended for patients with a urinary protein-to-creatinine ratio (UPCR) of 1.5g/g or greater, but this specification has been removed from the drug's label following the approval.
The Kidney Disease: Improving Global Outcomes (KDIGO) Draft Guidelines have also recognized Filspari as a foundational treatment for IgAN, while also lowering the proteinuria level required for treatment goals. These developments are seen as positive for both Filspari and Travere Therapeutics.
Canaccord Genuity has revised its model to reflect an increased peak U.S. market penetration forecast for Filspari, now estimated at 13.8% by 2031, up from the prior projection of 13.5%.
Moreover, the probability of success for Filspari in the U.S. market has been adjusted to 100%, up from 85%. This reflects an expectation of increased sales for the remainder of 2024 and into 2025, driven by the expanded drug indication associated with the FDA's full approval.
In other recent news, Travere Therapeutics has experienced notable progress with its drug FILSPARI, which has gained full FDA approval for the treatment of adult patients with primary Immunoglobulin A nephropathy (IgAN) at risk of disease progression.
The approval was based on the drug's proven ability to better preserve kidney function over the long term, as demonstrated in the Phase 3 PROTECT study. As a result of this approval, the eligible patient population is expected to grow from an initial estimate of 30,000-50,000 to approximately 70,000, leading to a projected increase in sales.
Citi and BofA Securities have both maintained their Buy ratings on Travere Therapeutics, with Citi raising its price target to $23.00 and BofA Securities increasing its price target to $19.00. These adjustments reflect the FDA's approval of FILSPARI and its potential to expand the market size.
In terms of financial performance, Travere Therapeutics reported FILSPARI sales reaching $27.1 million in the second quarter of 2024, a 37% increase over the first quarter. The company also reported a solid financial position, with $325.4 million in cash and securities, supporting its operations into 2028.
These recent developments underscore Travere's ongoing commitment to establishing FILSPARI as a foundational therapy for IgAN. The company anticipates further growth acceleration for FILSPARI following the upcoming PDUFA date for full approval.
InvestingPro Insights
In light of Canaccord Genuity's updated outlook on Travere Therapeutics, it's valuable to consider the financial health and market performance of the company. According to InvestingPro data, Travere has a market capitalization of approximately $983.68 million, reflecting its size and significance in the market. Despite a strong revenue growth of 47.42% over the last twelve months as of Q2 2024, the company's gross profit margin has been negative at -31.44%, indicating challenges in converting sales into net income.
Travere's significant price movements over the last year, with a one-month price total return of 50.76%, suggest a volatile yet potentially rewarding investment for those who can navigate the market well. An InvestingPro Tip highlights that Travere's stock is currently in overbought territory according to the Relative Strength Index (RSI), which could mean a potential retraction in price may be on the horizon. Conversely, the same tip indicates that the company's liquid assets exceed its short-term obligations, providing some financial stability in the near term.
For investors seeking more in-depth analysis, there are additional InvestingPro Tips available on https://www.investing.com/pro/TVTX. These tips may further guide investment decisions by providing insights into aspects such as cash burn rate, debt levels, and profitability expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.